Jump to any asset
849 assets, updated daily
As of October 10, 2026, Viking Therapeutics, Inc. (VKTX) trades at $28.51. CleaRank Financial AI rates it Buy with a fair value of $28.51, in line with the current price. Wall Street's consensus target is $95.00 across 20 analysts. RSI at 47 is in neutral territory, and the price is below its 50-day average of $32.79.
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. NASDAQ
$28.51
0.7800 (2.81%)
At close: Oct 9, 4:00 PM EDT
AI Analyst Consensus
79 / 100
Viking Therapeutics, Inc. (VKTX) is currently trading at $28.51, below its 50-day and 200-day moving averages ($32.79 and $33.01), indicating a bearish short-term trend. Despite this, Wall Street analysts maintain a strong conviction, with a median price target of $95, suggesting an upside potential of over 233%. The company operates in the Biotechnology sector, which has a median P/E of -6.10 and median revenue growth of 8.1%. Viking Therapeutics, Inc. has a very low debt-to-equity ratio of 0.01, indicating a strong balance sheet. Insiders have been net sellers of VKTX stock, with total sales exceeding $23.2 million against total purchases of approximately $150,000. This moderate sell signal suggests caution, though it is important to note that the company's profit margin and operating margin are currently 0.00%, and its return on equity is -88.85%, reflecting its stage of development as a clinical-stage biotechnology company. The lack of revenue growth reported in the data also highlights the speculative nature of the investment, which is heavily reliant on future drug development success.
VKTX Price Analysis
Market Metrics
Open
$27.85
Day Range
$27.58 to $28.86
Prev Close
$27.73
Volume
4.04M
52-Week Range
$25.04 to $43.15
Market Cap
$3.63B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
VKTX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, VKTX beat estimates 3 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
VKTX Analysis
Company's Health
3/5
AI Technical Analysis
Viking Therapeutics, Inc. (VKTX) is currently trading below its 50-day SMA of $32.79 and its 200-day SMA of $33.01, indicating a bearish trend. The RSI is at 47.16, suggesting neutral momentum, while the MACD is negative at -1.33, further reinforcing the current bearish sentiment. The stock's price is also below its 20-day EMA of $31.20. Key support levels are not clearly defined by the provided moving averages, as the stock is trading below all of them. Volume on the latest trading day was 4,036,200, which is below the average daily volume of 6,835,800, suggesting a lack of strong conviction from traders at current levels. The overall chart structure points to continued downward pressure in the near term unless a significant catalyst emerges.
ProTips
- Consider the significant insider selling activity, with over $23.2 million in sales, as a signal of caution despite the optimistic analyst targets.
- Viking Therapeutics, Inc. is trading below its 50-day and 200-day moving averages ($32.79 and $33.01), suggesting potential for further downside in the short term.
- Given the company's development stage and reliance on pipeline success, risk management and position sizing are paramount for investors.
Key Catalysts
Bullish
Positive Clinical Trial Data
Successful progression of VKTX's drug candidates through clinical trials, particularly in areas like NASH or obesity, could lead to significant upward price movement.
Source: Company Pipeline UpdatesBullish
Analyst Upgrades and Increased Price Targets
Continued positive sentiment from Wall Street analysts, potentially leading to further upgrades and price target increases beyond the current median of $95.
Source: Wall Street ResearchBearish
Clinical Trial Failures or Delays
Any negative results or significant delays in the clinical development of VKTX's drug candidates could severely impact investor confidence and stock price.
Source: Clinical Trial ResultsBearish
Insider Selling Trend Continues
If the moderate sell signal from insiders persists or intensifies, it could signal a lack of confidence in the company's near-term prospects.
Source: SEC FilingsMarket Outlook
The base case scenario for Viking Therapeutics, Inc. (VKTX) anticipates a significant upward revaluation, driven by the substantial upside indicated by Wall Street analysts' median price target of $95. This target suggests a potential for over 233% growth from the current trading price of $28.51. The company's minimal debt and strong balance sheet provide a stable foundation for its ongoing drug development efforts. However, the trajectory hinges critically on the success of its clinical pipeline and the eventual commercialization of its drug candidates. Any setbacks in clinical trials, regulatory hurdles, or competitive pressures could significantly alter this outlook. The current technical setup, with the stock trading below key moving averages and moderate insider selling, warrants a cautious approach until positive clinical data or regulatory approvals materialize.
Key Statistics
| Market Cap | 3.63B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -4.67 |
| Dividend Yield | 0.00% |
| 52 Week High | 43.15 |
| 52 Week Low | 25.04 |
Viking Therapeutics, Inc. (VKTX) exhibits a negative P/E ratio due to its negative EPS of -$4.67, making traditional valuation metrics difficult to apply. The company's profit and operating margins are both 0.00%, and its return on equity stands at a negative 88.85%, reflecting its status as a development-stage biotechnology firm without current product sales. Its debt-to-equity ratio is exceptionally low at 0.01, indicating minimal financial leverage. Compared to the Healthcare sector's median P/E of 31.9 and median revenue growth of 8.1%, VKTX's lack of revenue and negative EPS places it at a significant valuation discount on current fundamentals. The company's valuation is therefore entirely dependent on the success of its drug pipeline, rather than current financial performance.
Earnings & Growth Analysis
Viking Therapeutics, Inc. (VKTX) reported mixed earnings results. In the quarter to June 2026, the company reported an EPS of $0.89, beating the estimate of $0.87 by 2.3%, though the stock price declined by 1.27%. Prior to that, in the quarter to March 2026, VKTX reported an EPS of $0.07, exceeding the estimate of $0.05 by 40%, with a positive price reaction of 1.07%. However, the quarter to March 2026 also saw a significant miss, with an EPS of -$1.37 against an estimate of -$0.91, a surprise of -50.55%. The company's reported revenue growth is N/A, and forward-looking revenue estimates are $0 for the next quarter and current year.
Key Risks
Viking Therapeutics, Inc. (VKTX) faces significant risks due to its clinical-stage development status, with no reported revenue and negative EPS. The moderate insider selling signal, with over $23.2 million in sales versus $150,000 in purchases, suggests a lack of immediate confidence from management. Also, the stock is trading below key technical indicators, including its 50-day and 200-day SMAs, indicating potential for further downside pressure.
Technical Indicators
| RSI (14) | 47.16 |
|---|---|
| MACD | -1.33 |
| SMA 50 | 32.79 |
| SMA 200 | 33.01 |
RSI
Neutral
SMA Cross
Neutral
Price vs SMA
Bearish
MACD
Bearish
Price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.30
Weak correlation
Nasdaq 100 (QQQ)
+0.30
Weak correlation
Bitcoin (BTC)
+0.22
Weak correlation
Gold (XAU)
+0.10
Weak correlation
Check Custom Correlation
How does any other asset move with VKTX? One year of daily closes, Pearson correlation.
Try
VKTX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$27.94
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$28.51
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$24.77
MAX LOSS
-11.4%
Volatility-Adjusted Stop Loss
Calculated based on RSI (47.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$29.34
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$30.73
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$32.13
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
VKTX is classified as a high-volatility asset (Daily Vol: 7.56%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on October 10, 2026.Growth of $10,000
A $10,000 investment in VKTX in October 2016 would be worth about $221,008 today, compared with about $36,018 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VKTX today could grow to about $47,962 by 2036 in the base case, with a bull case near $363,870 and a bear case around $6,322. Projections are statistical simulations, not guarantees.
VKTX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $53.38 for VKTX by 2030 in the base case, from $28.51 today (1.9x over 4 years). The downside path ends near $14.82. These are outcomes of a Monte Carlo simulation run on VKTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $17.57 | $33.35 | $63.30 |
| 2028 | $15.76 | $39.01 | $96.55 |
| 2029 | $15.04 | $45.63 | $138 |
| 2030 | $14.82 | $53.38 | $192 |
| 2031 | $14.90 | $62.44 | $262 |
| 2032 | $15.20 | $73.04 | $351 |
| 2033 | $15.68 | $85.43 | $466 |
| 2034 | $16.31 | $99.93 | $612 |
| 2035 | $17.10 | $117 | $799 |
| 2036 | $18.02 | $137 | $1,037 |
Method: 10,000 simulated price paths using VKTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. VKTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
VKTX Insider Trading Analysis
Bought
$149.9K
1 Transactions
Sold
$23.2M
14 Transactions
Insiders
10
Active Traders
Avg Transaction
$1.6M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 1, 2024 | MANCINI MARIANNA
Chief Operating Officer
|
Sell | 281.4K | $22.1M |
| Sep 20, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 216.1K | $15.3M |
| Oct 28, 2024 | ZANTE GREGORY S
Chief Financial Officer
|
Sell | 131.7K | $10.1M |
| Jan 6, 2025 | LIAN BRIAN
Chief Executive Officer
|
Sell | 194.5K | $8.3M |
| Jan 5, 2026 | LIAN BRIAN
Chief Executive Officer
|
Sell | 233.4K | $7.7M |
| Aug 19, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 112.9K | $7.4M |
| Feb 8, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 269.1K | $7.2M |
| Jul 30, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 115.9K | $6.7M |
| May 3, 2024 | ZANTE GREGORY S
Chief Financial Officer
|
Sell | 66.8K | $5.0M |
| Jul 29, 2026 | LIAN BRIAN
Chief Executive Officer
|
Sell | 148.5K | $4.9M |
Page 1 of 1
Frequently Asked Questions
What is Viking Therapeutics, Inc.'s stock price forecast for 2030?
Based on Monte Carlo simulations, Viking Therapeutics, Inc.'s stock price is projected to be $53.38 in 2030 under a base case scenario. The downside projection is $14.82, while the upside projection reaches $192.29. These figures represent statistical outcomes and are not guaranteed price targets.
Is Viking Therapeutics, Inc. (VKTX) a buy right now?
Wall Street analysts rate Viking Therapeutics, Inc. (VKTX) as a Buy, with a consensus score of 79 out of 100. The median analyst price target is $95, indicating a substantial upside potential of 233.2% from the current price of $28.51.
What are the recent earnings trends for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. has reported mixed earnings, with some quarters beating estimates, such as the quarter to March 2026 where EPS was $0.07 against an estimate of $0.05. However, other quarters have shown significant misses, like the -$1.37 EPS reported for the quarter to March 2026 against an estimate of -$0.91.
How does Viking Therapeutics, Inc. compare to its sector averages?
Viking Therapeutics, Inc. (VKTX) operates in the Healthcare sector. While the sector has a median P/E of -6.10 and median revenue growth of 8.1%, VKTX reports N/A for revenue growth and has negative EPS, indicating it is valued based on future potential rather than current financial performance.
What is the insider sentiment for Viking Therapeutics, Inc. stock?
Insiders at Viking Therapeutics, Inc. are net sellers, with total sales of $23.2 million compared to total purchases of $150,000. This 'Moderate Sell Signal' suggests caution, although it is important to consider the company's development stage.
What are the key technical indicators for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. (VKTX) is currently trading below its 50-day SMA ($32.79) and 200-day SMA ($33.01), indicating a bearish trend. The RSI is neutral at 47.16, and the MACD is negative, reinforcing the current bearish technical setup.
What is the financial health of Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. maintains a very strong balance sheet with a debt-to-equity ratio of only 0.01. However, its profit margin and operating margin are 0.00%, and its return on equity is a negative 88.85%, typical for a clinical-stage biotechnology company.